Skip to main content

13-12-2019 | Breast cancer | Video

SABCS 2019 | No improvement in TNBC pathological complete response with atezolizumab addition

Luca Gianni outlines initial results from the NeoTRIPaPDL1 study of neoadjuvant atezolizumab plus chemotherapy in triple-negative breast cancer, and speculates on the reasons behind the differences with the KEYNOTE-522 findings (3:57).

Funding for independent interviews at SABCS 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits